Clinical Trials Logo
  1. Home
  2. Opioid Overdose
  3. NCT04317053

Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

Opioid Overdose Clinical Trial

Official title:
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

Clinical Trial Summary

The New York City (NYC) Department of Health and Mental Hygiene (DOHMH) has implemented Relay, a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. The proposed randomized controlled trial will evaluate the impact of Relay on preventing subsequent opioid-related adverse events. A total of 350 eligible individuals with nonfatal opioid OD presenting to one of four participating EDs will be enrolled and randomized to one of two arms: 1) site-directed care (SDC) or 2) Relay-peer-delivered OD education and treatment linkage, including 90 days of peer navigation. Outcomes will be measured for 12 months through interviews and administrative health data.

Clinical Trial Description

Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04317053
Study type Interventional
Source NYU Langone Health
Contact
Status Completed
Phase Phase 3
Start date October 8, 2020
Completion date July 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Recruiting NCT03924505 - Preventing Opioid Overdose Mortality in the United States N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Completed NCT05219669 - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Phase 1
Recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Suspended NCT05114460 - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal Phase 2
Not yet recruiting NCT05876572 - Blood Naloxone Levels Following Intradermal Injection in Humans Phase 4
Completed NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting NCT05944133 - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed NCT05377255 - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults Phase 1
Not yet recruiting NCT05877118 - Improving Availability of Intranasal Naloxone N/A
Recruiting NCT05072249 - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn NCT05808881 - Clinical Outcomes From Nalmefene Phase 4
Not yet recruiting NCT01622504 - Naloxone Nasal Spray Pharmacokinetic Study Phase 1
Completed NCT05506267 - Development of a Tracheal Sound Sensor
Completed NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Completed NCT04713709 - A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Phase 1
Active, not recruiting NCT05008523 - Opioids and Police Safety Study N/A
Completed NCT05363501 - Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers Phase 1